my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
02-03-2012: Exosome Diagnostics GmbH, a subsidiary of Exosome Diagnostics, Inc., and the Department of Dermatology at the Ludwig Maximilian University (LMU) announces the awarding of a EUR one million grant from the German Federal Ministry for Education and Research (BMBF) to develop blood-based diagnostic tests from the stable RNA content accessible in plasma-derived exosomes. The grant will help fund development of exosome-based diagnostics technology to detect tumor specific mutations in the blood from patients with malignant cancer in order to enable monitoring of disease recurrence, aid therapy selection and possibly improve early tumor detection. The grant was awarded under the Leading-Edge Cluster program "m4 – Personalized Medicine and Targeted Therapies."
Cancer tumor-specific somatic mutations such as those found in the RAF and RAS gene families will be investigated by coupling exosome-based technology with next-generation sequencing and qPCR instrument platforms. Exosome Diagnostics GmbH intends to offer clinical diagnostic tests developed under this project as a commercial laboratory service performed out of the Company's St. Paul, Minnesota, United States and Munich, Germany, cGLP laboratories.
"Exosome technology allows us to repeatedly interrogate tumor, inflammatory and immune response gene signatures in a minimally invasive manner," said James McCullough, chief executive officer, Exosome Diagnostics. "We are essentially looking for genetic needles in a haystack of biological material. By isolating exosomes we avoid a host of complicating factors, such as circulating enzymes, platelets, and other interfering factors, that are a significant detriment to achieving diagnostic sensitivity and reproducibility."
Microvesicles, of which exosomes are a subset, contain large quantities of tumor-derived messenger RNA (mRNA) found in biofluids outside of tumor cells. Microvesicle mRNA, is of high quality and includes both small and large RNA molecules in multiple copies. The microvesicle/exosome population provides a stable source of RNA in blood, urine and CSF that, when isolated and prepared properly, can produce high diagnostic sensitivity for key gene mutations and gene expression levels.
Exosome RNA biofluid diagnostic tests have potentially significant implications for disease identification, treatment and monitoring. In many cases, tumor tissue is difficult to attain and requires either a biopsy or a surgical procedure. Repeated blood and urine measurements are minimally invasive and can provide critical information on a tumor's genetic status over time, through the course of treatment and recurrence.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Exosome Diagnostics GmbH, a subsidiary of Exosome Diagnostics, Inc., and the Department of Dermatology at the Ludwig Maximilian University (LMU) announces the awarding of a EUR one million grant from the German Federal Ministry for Education and Research (BMBF) to develop blood-based diagno ... more
Exosome Diagnostics Announces Expansion of Scientific Advisory Board
Exosome Diagnostics announced the appointments of Bob Carter MD, Carlos Cordon-Cardo MD, PhD, Keith Flaherty MD, John Quackenbush, PhD; to its Scientific Advisory Board (SAB). Dr Carter is Professor and Chief of Neurosurgery at the University of California, San Diego Medical Center (UCSD) a ... more
Key Genes Associated with Cancer Found in Circulating Blood Microvesicles
Exosome Diagnostics Inc. announced that a team led by Dr. Johan Skog has published new findings showing that microvesicles shed in circulation contain powerful genetic elements, called retrotransposons, associated with cancer cell growth. Dysregulation of retrotransposons has been observe ... more
Exosome Diagnostics is a developer of proprietary non-invasive, molecular diagnostic tests. The company’s core technology is based on discoveries by Harvard and Massachusetts General Hospital researchers that circulating nanovesicles in blood and urine called exosomes contain unique geneti ... more
Exosome Diagnostics GmbH, a subsidiary of Exosome Diagnostics, Inc., and the Department of Dermatology at the Ludwig Maximilian University (LMU) announces the awarding of a EUR one million grant from the German Federal Ministry for Education and Research (BMBF) to develop blood-based diagno ... more
A possible new target for treatment of multiple sclerosis
The immune system recognizes and neutralizes or destroys toxins and foreign pathogens that have gained access to the body. Autoimmune diseases result when the system attacks the body's own tissues instead. One of the most common examples is multiple sclerosis (MS). MS is a serious condition ... more
Malaria medication may help against one type of Frontotemporal Dementia
Scientists at the German Center for Neurodegenerative Diseases (DZNE) and the Ludwig-Maximilians Universität Munich have found a promising approach for a possible treatment of so-called frontotemporal dementia, an Alzheimer-like form of dementia. Frontotemporal dementia is caused by a ... more
Pieris Receives BMBF Grant to Fund PRS-110 c-Met Antagonist Anticalin Program
Pieris AG announced the receipt of a EUR 1 million grant to support the development of the company’s proprietary PRS-110 compound targeting c-Met, a cellular receptor that plays a key role in cancer cell growth and metastasis. The goal of the funded research will be to delineate a biomarker ... more
Exosome Diagnostics GmbH, a subsidiary of Exosome Diagnostics, Inc., and the Department of Dermatology at the Ludwig Maximilian University (LMU) announces the awarding of a EUR one million grant from the German Federal Ministry for Education and Research (BMBF) to develop blood-based diagno ... more
BMBF PeTrA Project to make administration of biopharmaceuticals more tolerable for patients
The goal of the interdisciplinary research project PeTrA*, which is sponsored by the German Ministry for Education and Research (BMBF), is supersede the need for injections for biopharmaceuticals used e.g. in cancer immunotherapy by developing spray and tablet formulations which include inn ... more
Bundesministerium für Bildung und Forschung (BMBF)
Education forms the basis for one's whole life; research opens up previously unknown opportunities in all fields of life. Education and research need perspectives which extend far into the future. These are the foundations on which our future evolves. The BMBF's promotion of education and r ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2012 CHEMIE.DE Information Service GmbH, All rights reserved
